Cellebrite DI (CLBT) Capital Expenditures (2020 - 2025)

Cellebrite DI's Capital Expenditures history runs 6 years deep, the most recent figure standing at -$4.0 million for Q4 2025.

• In Q4 2025, Capital Expenditures fell 24.48% year-over-year to -$4.0 million; the TTM figure through Dec 2025 stood at -$13.2 million (down 54.39% YoY), while the FY2025 annual figure was $13.2 million, up 54.39% from the prior year.
• Capital Expenditures was -$4.0 million for Q4 2025 at Cellebrite DI, down from -$3.3 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $749000.0 in Q4 2021 to a low of -$4.0 million in Q4 2025.
• Historically, Capital Expenditures has averaged -$1.4 million across 5 years, with a median of -$1.2 million in 2022.
• The sharpest annual moves came in 2021 and 2023: Capital Expenditures jumped 1024.69% in 2021, then slumped 1469.62% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $749000.0 in 2021, then slumped by 285.71% to -$1.4 million in 2022, then tumbled by 62.47% to -$2.3 million in 2023, then plunged by 40.62% to -$3.2 million in 2024, then dropped by 24.48% to -$4.0 million in 2025.
• The last three Capital Expenditures figures came in at -$4.0 million (Q4 2025), -$3.3 million (Q3 2025), and -$3.6 million (Q2 2025), per Business Quant data.